Adaptimmune Therapeutics PLC Quarterly Common Stock, Shares Authorized from Q2 2014 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
Adaptimmune Therapeutics PLC quarterly Common Stock, Shares Authorized history and growth rate from Q2 2014 to Q3 2024.
  • Adaptimmune Therapeutics PLC Common Stock, Shares Authorized for the quarter ending September 30, 2024 was 2.04B shares, a 19.8% increase year-over-year.
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 2.04B +336M +19.8% Sep 30, 2024 10-Q 2024-11-13
Q2 2024 2.04B +336M +19.8% Jun 30, 2024 10-Q 2024-08-12
Q1 2024 1.7B +420M +32.7% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 1.7B +420M +32.7% Dec 31, 2023 10-Q 2024-11-13
Q3 2023 1.7B +420M +32.7% Sep 30, 2023 10-Q 2023-11-08
Q2 2023 1.7B +420M +32.7% Jun 30, 2023 10-Q 2023-08-09
Q1 2023 1.28B +41.9M +3.38% Mar 31, 2023 10-Q 2023-05-12
Q4 2022 1.28B +41.9M +3.38% Dec 31, 2022 10-K 2024-03-06
Q3 2022 1.28B +41.9M +3.38% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 1.28B +41.9M +3.38% Jun 30, 2022 10-Q 2022-08-04
Q1 2022 1.24B +203M +19.5% Mar 31, 2022 10-Q 2022-05-09
Q4 2021 1.24B +203M +19.5% Dec 31, 2021 10-K 2023-03-06
Q3 2021 1.24B +203M +19.5% Sep 30, 2021 10-Q 2021-11-04
Q2 2021 1.24B +203M +19.5% Jun 30, 2021 10-Q 2021-08-09
Q1 2021 1.04B +252M +32.1% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 1.04B +252M +32.1% Dec 31, 2020 10-K 2022-03-14
Q3 2020 1.04B +252M +32.1% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 1.04B +252M +32.1% Jun 30, 2020 10-Q 2020-08-06
Q1 2020 786M +84.8M +12.1% Mar 31, 2020 10-Q 2020-05-14
Q4 2019 786M +84.8M +12.1% Dec 31, 2019 10-K 2021-02-25
Q3 2019 786M +84.8M +12.1% Sep 30, 2019 10-Q 2019-11-06
Q2 2019 786M +84.8M +12.1% Jun 30, 2019 10-Q 2019-08-01
Q1 2019 701M 0 0% Mar 31, 2019 10-Q 2019-05-06
Q4 2018 701M 0 0% Dec 31, 2018 10-K 2020-02-27
Q3 2018 701M 0 0% Sep 30, 2018 10-Q 2018-11-06
Q2 2018 701M 0 0% Jun 30, 2018 10-Q 2018-08-02
Q1 2018 701M +126M +22% Mar 31, 2018 10-Q 2018-05-09
Q4 2017 701M +126M +22% Dec 31, 2017 10-K 2019-02-27
Q3 2017 701M +126M +22% Sep 30, 2017 10-Q 2017-11-02
Q2 2017 701M +126M +22% Jun 30, 2017 10-Q 2017-08-03
Q1 2017 575M 0 0% Mar 31, 2017 10-Q 2017-05-10
Q4 2016 575M 0 0% Dec 31, 2016 10-K 2018-03-15
Q3 2016 575M Sep 30, 2016 10-Q 2016-11-10
Q2 2016 575M 0 0% Jun 30, 2016 10-Q 2016-08-08
Q1 2016 575M Mar 31, 2016 10-Q 2016-05-12
Q4 2015 575M Dec 31, 2015 10-K 2017-03-13
Q2 2015 575M +364M +172% Jun 30, 2015 10-K 2017-03-13
Q2 2014 211M Jun 30, 2014 8-K 2016-07-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.